Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:11 pm
All countries
520,723,315
Recovered
Updated on June 26, 2022 8:11 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:11 pm
Tuesday, August 9, 2022

Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:11 pm
All countries
520,723,315
Recovered
Updated on June 26, 2022 8:11 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:11 pm
Molderizer and Safe Shield

Valneva working on remediation plan for COVID-19 vaccine candidate

Vir Biotechnology Provides Corporate Update and

– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing...

BA.5 Continues to Gain Ground, as Does Sublineage of BA.4 – NBC Chicago

According to the latest estimates from the Centers for Disease Control and Prevention, the BA.5 subvariant of COVID is still continuing to make...

China’s new iron chefs: Robots and AI dish out $4 menus in Shanghai

SHANGHAI -- Shanghai's newest "AI canteen" has all the hustle and bustle of a typical restaurant in China, except for one major distinction. Instead...


The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, 2021. REUTERS/Lisi Niesner

Register now for FREE unlimited access to Reuters.com

June 10 (Reuters) – French drugmaker Valneva (VLS.PA) said on Friday it had proposed a remediation plan after receiving the European Commission’s notice of intent to terminate the advance purchase agreement for its inactivated COVID-19 vaccine candidate.

“Some member states have confirmed their interest in having an inactivated, adjuvanted whole-virus vaccine solution in their portfolio,” the company said in a statement.

“However, the preliminary, unofficial volume indications received from the EC (European Commission) would not be sufficient to ensure the sustainability of Valneva’s COVID-19 vaccine programme.”

Register now for FREE unlimited access to Reuters.com

Valneva had warned on May 16 that its COVID-19 vaccine agreement with the European Commission was likely to be scrapped as Brussels had informed the company of its intent to terminate the advance purchase agreement. read more

“We hope that the EC and its member states will continue to evaluate the potential advantages of an inactivated vaccine,” Valneva Chief Executive Thomas Lingelbach said in a statement.

The drugmaker said that as a result it had proposed a remediation plan, which is now subject to further discussions within the EC and among the participating member states.

In parallel, the regulatory process with the European Medicines Agency (EMA) continues as planned, the company said, and the agency’s Committee for Medicinal Products for Human Use is set to take a final vote during the week of June 21 on whether to endorse the vaccine. In April, EMA asked the company to provide more data on the vaccine. read more

Register now for FREE unlimited access to Reuters.com

Reporting by Juliette Portala, editing by Angus MacSwan and Susan Fenton

Our Standards: The Thomson Reuters Trust Principles.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Vir Biotechnology Provides Corporate Update and

– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing...

BA.5 Continues to Gain Ground, as Does Sublineage of BA.4 – NBC Chicago

According to the latest estimates from the Centers for Disease Control and Prevention, the BA.5 subvariant of COVID is still continuing to make...

China’s new iron chefs: Robots and AI dish out $4 menus in Shanghai

SHANGHAI -- Shanghai's newest "AI canteen" has all the hustle and bustle of a typical restaurant in China, except for one major distinction. Instead...

Related Articles

Vir Biotechnology Provides Corporate Update and

– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing...

BA.5 Continues to Gain Ground, as Does Sublineage of BA.4 – NBC Chicago

According to the latest estimates from the Centers for Disease Control and Prevention, the BA.5 subvariant of COVID is still continuing to make...

China’s new iron chefs: Robots and AI dish out $4 menus in Shanghai

SHANGHAI -- Shanghai's newest "AI canteen" has all the hustle and bustle of a typical restaurant in China, except for one major distinction. Instead...